Objective: For most newborns, congenital heart defects (CHD) appear to be isolated anomalies and the brain is presumed to have normal developmental potential. Most studies of neurodevelopmental outcomes have focused on operative management strategies. Methods: Infants with complex CHD and no identified syndromes other than 22q11 microdeletions enrolled in a study of apolipoprotein E (APOE) polymorphisms and developmental outcome were evaluated at one year of age; including genetic evaluation and the Bayley Scales of Infant Development-II [mental (MDI) and psychomotor developmental indices (PDI)]. Results: Five hundred and fifty infants enrolled and 359 (20 with 22q11) of 501 survivors (72%) returned. Mean MDI was 90 AE 15 and PDI was 78 AE 18. Genetic syndromes not identified at birth were confirmed in 28 (8.1%) and suspected in 51 (15.0%). By multivariable analysis, suspected/confirmed genetic syndromes and APOE e2 allele predicted lower MDI and PDI, all p < 0.04. Lower birth weight ( p < 0.001) and preoperative intubation ( p = 0.012) predicted lower MDI. Higher hematocrit during the initial operation was associated with higher MDI ( p = 0.007). Longer postoperative length of stay was predictive of lower PDI ( p = 0.002). Additional operations with cardiopulmonary bypass were associated with lower MDI and PDI (both p < 0.002), but use of deep hypothermic circulatory arrest was not. Conclusions: Patient factors (birth weight and preoperative status) are significant determinants of neurodevelopmental outcomes as opposed to operative management strategies. In this cohort, genetic syndromes unsuspected at birth were surprisingly common and correlate with poor neurodevelopmental outcomes. Without multiple congenital anomalies, syndromes may be missed in infancy. Genetic evaluation should be considered in all infants with CHD. #
Introduction
Increasing focus has been directed towards the assessment of neurodevelopmental outcomes after neonatal cardiac surgery. For most newborns, congenital heart defects (CHD) appear to be isolated anomalies and the brain is presumed to have normal developmental potential. However, many infants who have undergone surgery for CHD in the neonatal period demonstrate a pattern of neurodevelopmental sequelae characterized by cognitive impairment, speech and language abnormalities, impaired visual-spatial and visual-motor skills, attention deficit/hyperactivity disorder (ADHD), motor delays and learning disabilities [1] . Central nervous system (CNS) injury in children with CHD is believed to be the result of a complex interaction of patientspecific factors (anatomic diagnosis and genetic susceptibility) and environmental influences (methods utilized in cardiac surgery, hypoxia in the preoperative period and socioeconomic status) [2] . The neurologic sequelae of cardiac surgery can be very subtle in young infants and the extent of impairment is often not fully recognized until long after the event when certain cognitive and higher executive functioning skills are required. The presence of neurologic injury can often be missed in infancy thus delaying intervention and therapy aimed at maximizing neurologic potential for such individuals. Most studies of neurodevelopmental outcomes after neonatal cardiac surgery have investigated the role of operative management strategies on short-and longer-term outcomes.
Apolipoprotein E (APOE) is an important regulator of cholesterol metabolism and has an important role as a neuroresiliency gene that modifies outcome following central nervous system injury. In 1998, we initiated a prospective study to evaluate the association between neurodevelopmental dysfunction and APOE genotype in neonates and infants undergoing surgery for CHD. We previously reported one-year outcomes for subgroups of the cohort, including those with tetralogy of Fallot (TOF) and hypoplastic left heart syndrome (HLHS) [2] [3] [4] [5] . We identified the APOE e2 allele as a risk factor for worse neurodevelopmental outcome at one year of age [3] . Neurodevelopmental outcomes at one year of age for the entire cohort have not been reported. In this study, we examined patient-specific factors and operative management variables as potential predictors of neurodevelopmental outcome in all surviving patients who returned for evaluation at one year of age.
Methods

Patient population
This is a prospective study assessing the effects of polymorphisms of the APOE gene on neurobehavioral outcomes at one year of age after cardiac surgery in infancy [3] . Patients 6 months of age undergoing surgery for CHD using cardiopulmonary bypass (CPB) with or without deep hypothermic circulatory arrest (DHCA) were eligible. Exclusion criteria included (1) multiple congenital anomalies, (2) recognizable genetic or phenotypic syndrome other than chromosome 22q11 microdeletion syndrome, and (3) language other than English spoken in the home. Infants born prematurely and infants with low birth weight were eligible for enrollment. In addition, infants with aortic arch obstruction and infants with functional single ventricle were also eligible. The study was approved by the institutional review board at The Children's Hospital of Philadelphia. Informed consent was obtained from the parent or guardian.
Operative management
Operations were performed by five cardiac surgeons with a dedicated team of cardiac anesthesiologists. Alpha-stat blood gas management was used. Pump flow rates were not standardized for this study. DHCA was used at the surgeon's discretion. The mean hematocrit after institution of CPB and hemodilution was maintained at 26 AE 3.5%. Before DHCA, patients underwent core cooling with topical hypothermia to a nasopharyngeal temperature of 18 8C. Modified ultrafiltration was performed in all patients following separation from CPB. Postoperatively, patients were managed in the cardiac intensive care unit (CICU) by a dedicated team of cardiologists and intensivists.
Data collection
Preoperative factors, which might independently affect neurobehavioral outcomes, including gestational age, birth head circumference, and birth weight were obtained from birth and hospital records. Weight and age at surgery were recorded for the initial operation and subsequent procedures with CPB. Operative variables were recorded, including the duration of CPB and DHCA, lowest NP temperature and hematocrit (HCT) after hemodilution.
Genetic evaluation
All patients were examined by a medical geneticist with expertise in dysmorphology at one year of age. Because recognition of genetic syndromes in neonates may be difficult, some children with genetic abnormalities had been enrolled as infants. Chromosome analysis and other genetic testing including that for microdeletions of chromosome 22q11 were performed as indicated.
APOE genotype determination
Whole blood was obtained before the operation and stored at 4 8C. Genomic DNA was prepared and used to determine APOE genotypes by using a previously published method [6] .
One-year neurodevelopmental examination
Children were evaluated at 12 months of age AE 2 weeks, corrected for prematurity. All study personnel were blinded to the APOE genotype. Developmental outcomes were assessed using the Bayley Scales of Infant Development-II (BSID-II), which yields two scores: the psychomotor development index (PDI) and the mental developmental index (MDI). The MDI assesses memory, problem solving, early number concepts, generalization, vocalizations and language and social skills. The PDI assesses gross muscle function, including crawling and walking, as well as fine muscle function and muscle skills necessary for prehension, use of writing instruments, and imitation of hand movements. Both the MDI and PDI are normalized to a mean of 100 with a standard deviation (SD) of 15. They yield an accurate assessment of a child's developmental status at one year, but have limited predictive validity for later outcomes, such as intelligence quotient (IQ) or behavior in adolescence. The evaluation also included medical history, growth measurements, and detailed neurological examination assessing active and passive tone, reflexes, gross motor skills, and visual and auditory responses. The ethnicity of the child and the familial socioeconomic status (SES) were also documented. Ethnicity was classified as Asian-Pacific, black, Hispanic, native American, other, or white as reported by the parent. SES was assessed by parental report using the Hollingshead scale [7] .
Data analysis
Patients were coded according to a previously described classification incorporating anatomy and perioperative physiology that has been shown to be predictive of perioperative mortality in neonates [8] . Class I includes patients with two ventricles and no aortic arch obstruction (e.g., transposition of the great arteries [TGA], tetralogy of Fallot), class II includes patients with two ventricles with aortic arch obstruction (e.g., coarctation with ventricular septal defect [VSD]), class III includes patients with single ventricle with no arch obstruction (e.g., tricuspid atresia with pulmonary atresia), and class IV includes patients with single ventricle with arch obstruction (e.g., hypoplastic left heart syndrome). Results of the genetic evaluations were classified as normal if no genetic or chromosomal abnormality was demonstrated, abnormal if a specific diagnosis was confirmed, and suspect if there was clinical evidence of a genetic syndrome that could not be confirmed with current genotyping techniques. Results of the neurologic examinations were classified as normal or only mild abnormalities that did not affect motor skills were found, suspect when there was a moderate degree of abnormality (e.g., moderate hypotonia with generally normal reflexes and mildly abnormal motor skills), and abnormal whenever significant abnormalities of tone, reflexes or motor skills were present.
Data are presented as either median (range) or mean AE standard deviation, as appropriate. All predictors listed were tested by linear regression for univariate prediction of MDI, PDI, and head circumference, and logistic regression for prediction of neuromuscular outcome (0 = 'normal', 1 = 'abnormal/suspect'). Estimates for logistic regression models are given as log odds. Patients were grouped according to their primary cardiac diagnosis. Subjects were grouped by APOE genotype into the e2 group (e2e2 and e3e2), the e3 group (e3e3) and the e4 group (e3e4 and e4e4). Categorical variables were coded as dummy variables, with the most common category as the reference group and the overall model p value used. For each outcome, all predictors with a marginal p < 0.1 were considered in separate backward and forward stepwise logistic regressions. The most parsimonious model was chosen to determine a model for prediction of each outcome. Stepwise model results are given for predictors with p values < 0.05. Use of DHCA was also considered separately from the quantitative variable duration of DHCA. All analyses used SPSS 10.0 for Windows (SPSS Inc., Chicago, IL) and the R statistical software environment.
Results
Study population
Between September 1998 and April 2003, 675 eligible infants underwent cardiac surgery. Twenty-three infants died prior to consent, parents of 102 declined participation and 550 (81%) were enrolled. Twenty-one patients (3.8%) died during the initial hospitalization, and 28 (5.3%) additional patients died after hospital discharge before one year of age. Three hundred and fifty-nine of 501 survivors at one year (72%) returned for evaluation. The study population was 65% caucasian, 23% African-American, and 12% other ethnic origins; 58% were male. The largest diagnostic groups are HLHS (n = 121), TOF (n = 83), VSD with or without coarctation (n = 77), and TGA with or without a VSD (n = 45). APOE genotyping was completed in 540/550 (98%). The APOE genotype distribution is: e2e2 (3), e2e3 (64), e2e4 (14), e3e3 (323), e3e4 (124), and e4e4 (12); and is not different from Hardy-Weinberg proportions.
Preoperative and intraoperative characteristics were compared for the 359 returning patients, the 142 patients who did not return and the 49 patients who expired prior to one year of age (Table 1) . Caucasian patients were more likely to return whereas there is an under-representation of African-American patients in the returning group (17% vs 37%).
One-year genetic evaluation
The genetic evaluation was considered normal in 257 (72%) of the 359 patients returning for one-year evaluation. Microdeletions of 22q11 were identified in 20 patients. In addition, genetic diagnoses not identified at birth were confirmed in 28 (8.1%) ( Table 2 ). Genetic syndromes were suspected, but not confirmed in an additional 51 patients (15.0%). The genetic status is unknown for three patients for whom the evaluation was not completed. There was no association of APOE genotype with the genetic classifications. Patient ethnicity was similar across all genetic categories. However, gestational age, birth weight and birth head circumference measurements are all significantly lower in patients with confirmed genetic syndromes compared to those with no identifiable anomaly (Table 3 ).
One-year neurodevelopmental evaluation
Overall scores for both the MDI and PDI are lower than population norms. Consistent with previous studies, motor skills as assessed by the PDI and the neuromuscular exam are more significantly impaired after cardiac surgery in infants than is cognitive function as assessed by MDI. For the entire cohort (n = 359), the mean MDI was 89.8 AE 14.9 and the mean PDI was 79.0 AE 23.0. There was a consistent decrease in scores related to the genetic evaluation, highest in those without genetic syndromes, and lowest in those with confirmed genetic syndromes; those with suspected genetic abnormalities had scores intermediate between the two. For the patients without genetic syndromes (n = 256), the mean MDI was 93.3 AE 13.1 and the mean PDI was 82.0 AE 16.1. For those 51 patients with suspected genetic abnormalities, the MDI was 86.9 AE 14.1 and the PDI 73.5 AE 21.5. In the group with confirmed genetic syndromes, the mean MDI and PDI were 74.0 AE 14.2 and 59.8 AE 12.3, respectively (Table 4) . For the 22q11 microdeletion subgroup, the mean MDI was 75.8 AE 12.3, the mean PDI was 61 AE 12.7 and the average head circumference was 44.3 AE 1.5. MDI and PDI scores were similar for patients with 22q11 microdeletions and those with other confirmed genetic syndromes (Fig. 1) .
Stepwise logistic regression for MDI identified the APOE e2 allele, a confirmed or suspected genetic syndrome, and preoperative intubation as significant predictors of a lower MDI score (Table 5A ). Higher birth weight and higher HCT during the initial procedure predicted higher MDI scores. Additional operations with CPB prior to the assessment at one year of age were associated with lower MDI scores. Interestingly, use of DHCA during additional surgery was associated with higher MDI scores. For the PDI, stepwise logistic regression identified the APOE e2 allele, a confirmed or suspected genetic syndrome, longer postoperative length of stay, lower SES and additional operations with CPB prior to one year as predictors of lower PDI scores (Table 5B ). As seen in the general population, African-American race was predictive of a higher score on the PDI at one year of age than those for other ethnic groups [9, 10] .
The neuromuscular examination was abnormal or suspect in 144 patients (40.2%). The most common abnormality on neuromuscular examination was hypotonia. Predictors of abnormal neuromuscular examination as identified by stepwise logistic regression were confirmed genetic syndrome, preoperative intubation, 'more complex' CHD (higher diagnostic class), and a longer postoperative length of stay (Table 6 ). Increased birth weight was associated with a better neuromuscular examination at one year. As in the PDI, African-American race was also significantly associated with better performance on the neuromuscular examination at one year. Head circumference at one year of age was assessed as a surrogate for brain growth. The median head circumference was 45.7 cm. Microcephaly, defined as head circumference percentile 5%, was present in 13 of 256 (5.1%) patients.
Stepwise logistic regression identified male gender as predictive of larger head circumference. A larger head circumference at birth and greater birth weight were also associated with larger head circumference at one year. The APOE e2 allele, confirmed or suspected genetic syndrome, Asian-Pacific race, black race, other race and lower gestational age were predictive of smaller head circumference at one year. Use of DHCA at the initial operation and need for postoperative mechanical support (extracorporeal membrane oxygenation [ECMO] or ventricular assist device [VAD]) were associated with smaller head circumference at one year (Table 7) .
Discussion
In the current study, we evaluated both patient-specific factors and operative management variables as modifiers of the risk for neurodevelopmental dysfunction at one year of age after cardiac surgery in a heterogeneous group of neonates and infants with CHD. Overall scores for both the MDI and the PDI are lower than population norms. Consistent with previous studies, motor skills as assessed by the PDI and the neuromuscular examination are more significantly impaired after cardiac surgery in infancy than is cognitive function assessed by the MDI [11] [12] [13] . These findings are consistent with the hypothesis that patient-specific factors such as birth weight, ethnicity, and the presence of a genetic syndrome are important determinants of neurodevelopmental outcome after cardiac surgery in neonates and infants [2] . Specific operative management strategies had little impact on outcome, with the important exception of a higher HCT after hemodilution, which was associated with better outcomes. Importantly, neither the use nor the duration of DHCA was associated with a worse outcome at one year of age for MDI, PDI or neuromuscular examination, although it was associated with a smaller head circumference at one year of age. Interestingly, more complex forms of CHD and need for additional operations during the first year of life were associated with worse outcomes. The need for preoperative intubation, longer postoperative length of stay and use of ECMO or VAD were all associated with worse neurodevelopmental outcomes suggesting that hemodynamic instability, respiratory difficulties and events in the CICU, both before and after surgery, are important risk factors for adverse neurodevelopmental outcomes.
In addition, the current study confirms and extends our preliminary report in a subgroup of the cohort that the APOE e2 allele is associated with a worse neurodevelopmental outcome [3] . This finding is consistent with the hypothesis that genetic variants that do not cause CHD may alter the response to environmental factors and thus increase susceptibility to neurologic injury. An additional important finding is the high prevalence of genetic syndromes that were unsuspected in the newborn period. Despite attempting to exclude patients with genetic syndromes other than 22q11 microdeletions, formal genetic evaluation at one year of age identified confirmed or suspected genetic abnormalities in over 20% of the cohort. This suggests that genetic abnormalities are common in children with CHD, even in the absence of additional congenital anomalies. The presence of these genetic diagnoses was associated with significantly worse neurodevelopmental outcome at one year of age. Formal genetic evaluation should be considered in all newborns with CHD and studies of neuroprotective strategies should stratify for genetic diagnoses.
Neurodevelopmental dysfunction is one of the most common and potentially disabling outcomes of CHD and its treatment. In the current study, we evaluated neurodevelopmental outcomes in 359 children at one year of age following infant cardiac surgery; the largest cohort of children with CHD and serial neurodevelopmental evaluations ever reported. The study population is ethnically diverse, 42% female, and includes patients with complex CHD, including HLHS. For comparison, the largest previous study evaluating neurodevelopmental outcomes after neonatal cardiac surgery Boston Circulatory Arrest Study (BCAS), by design, was limited to patients with TGA (n = 171) and was comprised primarily of caucasian (89%) males (76%) [14] . To minimize confounding factors for longer-term outcomes, the BCAS excluded some patients included in the current study such as those with a birthweight <2.5 kg, significant extracardiac anomalies and anatomy requiring aortic arch reconstruction or additional open procedures. Thus, the APOE cohort is more diverse than the BCAS cohort in terms of gender, race, and cardiac defect; increasing the potential for generalization of findings to the larger CHD population.
Many previous observational studies and neuroprotective trials in this population have focused on potentially modifiable risk factors, particularly intraoperative management strategies. The current study supports previous work suggesting that higher hematocrit after hemodilution is associated with better neurodevelopmental outcomes. In contrast, the current study does not support the avoidance of limited periods of DHCA. This discrepancy is likely multifactorial, as the current study is much more diverse in terms of cardiac diagnoses, perioperative and intraoperative support strategies and patient-related risk factors such as gender and ethnicity. It was also conducted in a much more recent era, including considerably different postoperative management strategies than in the BCAS other factors in addition to intraoperative support techniques, in the BCAS, infants undergoing the arterial switch procedure between 1988 and 1992 for TGA with or without VSD were prospectively randomized to an operative support strategy of either primarily DHCA or primarily continuous low-flow CPB. At the four-year evaluation, cognitive function assessed by full scale, verbal, and performance IQ was significantly lower for the entire cohort compared with the general population, but there was no treatment group effect [15] . Social class predicted a larger percentage of the variation in IQ (24%) than did treatment group (DHCA vs low-flow CPB) assignment (3%). Similarly, at the eight-year evaluation, performance of the cohort for many neurodevelopmental domains was worse than population norms, with no effect of treatment group assignment [16] . As at the four-year a Interval CPB and DHCA times are for operation, which occurred after the initial procedure but prior to one year of age. evaluation, SES (23.7%) and VSD status (3.2%) explained more of the variance in IQ than did treatment group assignment (0.3%). As part of a subsequent, prospective, randomized study investigating blood gas management strategies (alphastat vs pH-stat) during CPB, these investigators evaluated neurodevelopmental outcomes at one year of age [12] . The investigators concluded that neither strategy was consistently associated with improved or impaired outcomes. They also evaluated lower HCT after hemodilution as a risk factor for worse neurodevelopmental outcomes at one year in two separate trials. A HCT less than 24% was associated with lower PDI scores at one year. Overall, these studies suggest that factors other than intraoperative management strategies may be more important determinants of neurodevelopmental outcomes for many children [12] . The western Canadian complex pediatric therapies project follow-up group has prospectively evaluated neurodevelopmental outcomes in several cohorts of infants with complex CHD [17] . They reported neurodevelopmental outcomes at 18-24 months of age in 82 infants with TGA. Mean MDI was 89 AE 17 and mean PDI was 92 AE 15. As in the current study, CPB and DHCA times were not predictive of developmental outcome. Preoperative variables of low gestational age and high preoperative lactate correctly classified 84.1% of mentally and/or motor-delayed children. In another study, they evaluated outcomes in 34 survivors of repair of total anomalous pulmonary venous connection (TAPVC). By multivariable regression, no operative support variables were predictive of MDI or PDI at 18-24 months of age. The only significant predictor of MDI was SES and the only predictors of PDI were lower weight at surgery and higher postoperative lactate levels. These investigators have also evaluated outcomes at five years of age in children following repair of complex CHD, including TGA, TAPVC, and HLHS. Children with chromosomal abnormalities had lower full scale and verbal IQs at five years than other survivors, with no differences found among the remaining groups. The findings of these studies conducted in the most recent era of cardiac surgery and postoperative care are consistent with the findings of the current study, confirming that patient-specific factors, especially genetic anomalies, are more important predictors of neurodevelopmental outcomes than are operative support techniques.
ApoE-containing lipoproteins are the primary lipid transport vehicles in the CNS and have an important role in mobilization and redistribution of cholesterol and phospholipids during remodeling of neuronal membranes [18, 19] . The gene for the human APOE is located on chromosome 19 and codes for a 299 amino acid (AA) protein. The most common allele in man is e3, with two other common alleles, e2 and e4, whose protein products differ from that of e3 by single AA substitutions. APOE genotype is an important modulator of the response to traumatic brain injury (TBI) and neurodevelopment [20] . The APOE e4 allele is associated with increased risk of developing dementia and worse prognosis following TBI in adults. However, the effects of APOE genotype on recovery are not the same in the immature, developing brain as in the aging brain. Unlike adults, better functional recovery following TBI has been reported in children with the e4 allele, compared to those without [21] . In a study of lead exposure, the e4 allele was associated with a 4.4 point higher score on the MDI [22] . APOE genotype modifies the adverse effects of lead exposure. Negative effects of lead exposure on the MDI are 4-fold greater for e2 and e3 carriers compared to e4 carriers. Chronic diarrhea with malnutrition is associated with deficits in cognition and executive function [23] . In children who suffered multiple diarrheal episodes early in life, the e4 allele is associated with better visual working memory and semantic fluency. APOE e2 carriers have a 12-fold increased risk of cerebral palsy and e4 carriers a 5-fold increase [24] . The consistent negative effects of the e2 allele are consistent with its lower frequency in populations. The available evidence suggests that differences in apoE proteins result in altered CNS development and recovery from injury, with significant functional consequences. Importantly, recent research suggests therapeutic interventions based on APOE genotype may be possible. Intrathecal delivery of an apoE-mimetic peptide in a neonatal mouse model caused a significant reduction in post-ischemic brain necrosis; suggesting that administration of apoE-derived therapeutic peptides may ameliorate perinatal hypoxic/ischemic brain injury [25] .
Limitations
This study is a single-center, secondary analysis of an observational study evaluating APOE genotype as a risk factor for worse neurodevelopmental outcomes after infant cardiac surgery. It was not designed as a treatment trial and may be underpowered to determine differences in outcome resulting from changes in intraoperative management strategies, such as DHCA and HCT, as these strategies were not controlled or implemented in a protocol-driven fashion. The predictive value of neurodevelopmental testing at one year of age is limited. The full extent of an early injury often is not completely recognized until much later in life when more complex cognitive and executive skills are required. The BSID-II was used to assess the developmental level of survivors because this commonly used tool provides a good assessment of developmental strengths and weaknesses. It is, however, not an intelligence test and assessment of one-year mental and motor development may correlate only modestly with performance later in life.
Conclusions
In this large, heterogeneous group of patients undergoing repair of complex CHD in infancy, patient-specific, rather than surgical, factors are important determinants of neurodevelopmental outcomes at one year of age. Consistent with previous studies, most intraoperative management variables are not predictive of neurodevelopmental outcomes at one year of age, whereas genetic factors are a major determinant of neurologic outcome. In this cohort, genetic syndromes unsuspected at birth were common and correlated with poor neurodevelopmental outcomes; these syndromes may be difficult to diagnose in infancy and require ongoing evaluation in early childhood. There is also a significant effect of the APOE e2 allele, resulting in lower MDI and PDI scores at one year of age. This finding is consistent with the hypothesis that APOE genotype is associated with neuroresiliency after CNS injury. Future studies of neurological outcome and clinical trials of new neuroprotective strategies should include risk stratification for genetics and preoperative variables in relation to adverse neurologic outcomes. Formal evaluation by a medical geneticist is recommended for all infants with complex congenital heart disease as many of the syndromes go unnoticed in the neonatal period.
looked for risk factors for seizures, we could not identify genetic syndrome as a risk factor.
We identified seizures in 11% of the population, which was decreased from the rate identified in the Boston Circulatory Arrest Study. A seizure was not associated with a worse outcome at one year of age. In the Boston Circulatory Arrest Study seizures were associated with a worse outcome. They did not treat seizures. In that study, the investigators were blinded to the occurrence of a seizure and may not have known if an EEG seizure occurred until much later when the EEGs were read. Because of their finding that seizures were associated with a worse outcome, we didn't think we could ethically not treat a seizure once it was identified. So our EEGs were read on a continuous basis; and whenever we identified a seizure, we would initiate treatment. So we hopefully mitigated some of the adverse effects by early treatment.
In terms of the particular genetic anomalies, this is a rapidly evolving field. We are just beginning to learn. In the course of the study, the tests that our geneticist would utilize changed. In the early stages, the diagnosis was based on physical examination and clinical experience by the geneticist. Other tests were gradually introduced including FISH for 22q11 microdeletions and more recently whole genome scans with over 500K SNPs. So I think, as we go forward, we're going to identify many more genetic anomalies that are associated both with the presence of congenital heart disease, and also those such as the APOE e2 allele, which are not associated with any particular type of heart disease but affect how the brain recovers. So I think as we learn these, we should begin to include these in our databases.
Dr Maruszewski: How about strokes, did you observe the strokes? Dr Gaynor: We performed postoperative MRIs in 105 patients and we identified a 10% incidence of stroke, significantly less than our incidence of white matter injury in a previous study, and we did not see genetic syndromes as a risk factor for stroke.
Dr J. Vazquez-Jimenez (Aachen, Germany): I have a short question. Did you look at the relationship of the preoperative oxygen saturation and the development of problems afterwards? Because having had a very good group of hypoplastic left heart syndrome waiting for the second and the third operation, we think that the preoperative cyanosis or low oxygen saturations could explain a high percentage of these problems.
Dr Gaynor: We did not record saturations for several reasons. Oxygen saturation is tightly linked and very collinear with particular heart defects. There are certain heart defects which cause hypoxemia and cyanosis. Some patients are going to be cyanotic only for a very short period of time, such as a transposition who has an early switch. Others, as you suggest, such as HLHS patients are going to be cyanotic for a much longer period. So it's very tightly linked to the diagnosis and essentially colinear with the diagnosis. Also, it's difficult to know which saturation to measure. We've all observed pulse oximetry in a child which can vary in the same day and can be 90% or 70%. Is one value which is low important? I mean, if they are 90% for 23 h and 70% for 1 h, should we record 90% or 70%? So it's very difficult to know which particular saturation accurately reflects the child's clinical state. So we did not evaluate saturations because they are colinear with the defect and it's very hard to know which particular saturation accurately represents the child's state.
Dr V. Tsang (London, United Kingdom): Just a practical question. On the basis of what you found, has it changed your process of getting the consent, informed consent from the parents?
Dr Gaynor: In terms of. Dr Tsang: The future neurological development. Dr Gaynor: I always mention that there is a risk of brain injury, stroke, seizure, and that some of these kids will have problems down the road. We're not very good yet at predicting exactly who is at risk, but we know that many of them are, what I usually tell parents is that we know that a certain number of these kids will have problems in school and stuff, and it's very important to identify them early.
We should treat these patients as high-risk children, just like the neonatal units do with the preterm babies, and have prospective follow-up of their development and try to have a standardized plan for early intervention, which hopefully would improve the outcomes. If you identify the problems early and then begin your physical therapy, occupational therapy, speech therapy, whatever, very early, you hopefully can improve outcomes. It's a hypothesis that needs to be tested. So I always mention to the families that this is a possibility.
Dr Tsang: In our mind, when we offer such good surgical repair, we want to normalize the circulation. But in actual fact, we can only optimize because of the genetic background. There are so many events which are surfacing now which really make us think about what we actually do.
Dr Gaynor: Well, I think it's important to realize that the brains are not normal in these children at birth. We have been doing early preoperative MRIs and you can show the brains are small. And data that Dan Licht, one of our neurologists, presented at the AATS this year, show that the brains are immature at birth. In full-term babies, their development measured by the folding and myelination and glial migration is about four weeks less than a fullterm baby without congenital heart disease. So they're probably more susceptible to injury from hypoxia and other things. The brains are not normal at birth. And we're going to probably eventually have to begin pushing back into the intrauterine period, maybe doing things to try to accelerate brain maturation or even things such as treatment with white matter protective agents in utero.
